Organization
Epic Sciences, Inc.
7 abstracts
2 posters
Abstract
Use of multimodal circulating tumor cell assay to detect HER2-ultralow and ER co-expression matched with single-cell chromosomal instability in metastatic breast cancer.Org: Epic Sciences, Inc., San Diego State University Department of Biology, San Diego, CA, La Jolla, CA,
Abstract
Concordance between liquid and tissue biopsy in participants with newly diagnosed recurrent breast cancer.Org: Epic Sciences, Inc.,
Abstract
Validation of a single-cell sequencing assay for the detection of circulating tumor cells in metastatic breast cancer.Org: Epic Sciences, Inc.,
Abstract
Liquid biopsy identification of ERBB2 amplified and HER2 expressing metastatic breast cancer: Comparison and combination of cell and cell-free platforms.Org: Epic Sciences, Inc., Renown Health-Pennington Cancer Institute,
Abstract
Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus 177lutetium-prostate specific membrane antigen-617 (177Lu-PSMA-617) in the LuPARP trial.Org: Epic Sciences, Inc., Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Molecular Imaging and Therapeutic Nuclear Medicine,
Abstract
Validation of a 56 gene panel for the detection of somatic variants in metastatic breast cancer.Org: Epic Sciences, Inc.,
Abstract
Analysis of androgen receptor dynamics through immunofluorescent staining of circulating tumor cells in castration-resistant prostate cancer.Org: Memorial Sloan Kettering Cancer Center, Epic Sciences, Inc.,